BioCentury
ARTICLE | Company News

Almirall out-licenses RA compound to Aslan

May 21, 2012 11:34 PM UTC

Almirall S.A. (Madrid:ALM) granted Aslan Pharmaceuticals Pte. Ltd. (Singapore) worldwide rights to develop LAS186323, a dihydroorotate dehydrogenase (DHODH) inhibitor in Phase I testing for rheumatoid arthritis. Aslan will conduct and fund development through the end of Phase II trials, after which Aslan will find a partner for Phase III development and commercialization. Details were not disclosed. ...